

05-04-05

IFW



Express Mail Label No.: EV 533193418 US

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant(s): **Timothy J. Guzi et al.** : Group Art Unit: To Be Assigned
Serial No.: **10/776,988** : Examiner: To Be Assigned
Filed: **02/11/2004** :
For: **NOVEL PYRAZOLOPYRIMIDINES AS** : Attorney Docket No. : OC01617K1
CYCLIN DEPENDENT KINASE INHIBITORS : X

**INFORMATION DISCLOSURE STATEMENT AND
SUBMISSION OF INTERNATIONAL SEARCH REPORT**

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

Pursuant to Rule 56, it is requested that the documents listed on the accompanying PTO-1449 Form be considered and made of record in the above-identified patent application. Copy(ies) of these references are attached were filed in related application U.S. Serial No(s) _____ filed _____, respectively.

(b) No fee is believed due because:

- This Information Disclosure Statement is being filed within three (3) months of the filing date of the application.
- This Information Disclosure Statement is being concurrently filed with the above-identified application.
- This Information Disclosure Statement is being concurrently filed with a Request for Continued Examination (RCE).

This Information Disclosure Statement is being filed prior to the mailing of a first Office Action on the merits.

(c) This Information Disclosure Statement is being filed before the mailing date of any final action, notice of allowance or an action that otherwise closes prosecution; and

Each item of information contained in this Information Disclosure Statement was first cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this Information Disclosure Statement; or

No item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the undersigned after making reasonable inquiry, no item of information contained in this Information Disclosure Statement was known to any individual designated in § 1.56(c) more than three months prior to the filing of this Information Disclosure Statement; or

The Commissioner is hereby authorized to charge the requisite fee listed on the attached Fee Transmittal Sheet.

May 3, 2005

Page 2 of 2

(d) This Information Disclosure Statement is being filed on or before the payment of the issue fee; and

Each item of information contained in this Information Disclosure Statement was first cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this Information Disclosure Statement; or

No item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the undersigned after making reasonable inquiry, no item of information contained in this Information Disclosure Statement was known to any individual designated in § 1.56(c) more than three months prior to the filing of this Information Disclosure Statement; and

The Commissioner is hereby authorized to charge the requisite fee listed on the attached Fee Transmittal Sheet.

The Commissioner is hereby authorized to charge any additional fees which may be required for this Information Disclosure Statement, or credit any overpayment to Deposit Account No. 19-0365, Patent Case No. OC01617K1.

Respectfully submitted,
SCHERING-PLOUGH CORPORATION



By:

Name: Palaiyur S. Kalyanaraman
Reg. No.: 34,634
Attorney of Record
Telephone No.: (908) 298-5068

Dated: May 3, 2005
SCHERING-PLOUGH CORPORATION
Patent Department, K-6-1, 1990
2000 Galloping Hill Road
Kenilworth, NJ 07033-0530
Facsimile No.: (908) 298-5388



Express Mail Label No. EV 533193418 US

PTO/SB/21 (09-04)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995 no persons are required to respond to a collection of information unless it displays a valid OMB control number.

TRANSMITTAL FORM

(to be used for all correspondence after initial filing)

	Application Number	10/776,988
	Filing Date	02/11/2004
	First Named Inventor	Timothy J. Guzi
	Art Unit	To Be Assigned
	Examiner Name	To Be Assigned
Total Number of Pages in This Submission	Attorney Docket Number	OC01617K1

ENCLOSURES (Check all that apply)		
<input type="checkbox"/> Fee Transmittal Form <input type="checkbox"/> Fee Attached	<input type="checkbox"/> Drawing(s) <input type="checkbox"/> Licensing-related Papers	<input type="checkbox"/> After Allowance Communication to TC <input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences
<input type="checkbox"/> Amendment/Reply <input type="checkbox"/> After Final <input type="checkbox"/> Affidavits/declaration(s)	<input type="checkbox"/> Petition <input type="checkbox"/> Petition to Convert to a Provisional Application <input type="checkbox"/> Power of Attorney, Revocation <input type="checkbox"/> Change of Correspondence Address	<input type="checkbox"/> Appeal Communication to TC (Appeal Notice, Brief, Reply Brief) <input type="checkbox"/> Proprietary Information
<input type="checkbox"/> Extension of Time Request	<input type="checkbox"/> Terminal Disclaimer	<input type="checkbox"/> Status Letter
<input type="checkbox"/> Express Abandonment Request	<input type="checkbox"/> Request for Refund	<input checked="" type="checkbox"/> Other Enclosure(s) (please identify below):
<input checked="" type="checkbox"/> Information Disclosure Statement	<input type="checkbox"/> CD, Number of CD(s) _____ <input type="checkbox"/> Landscape Table on CID	PTO-1449 form - 2pgs. in duplicate References (23); Post Card
<input type="checkbox"/> Certified Copy of Priority Document(s)	<input type="checkbox"/> Remarks	
<input type="checkbox"/> Reply to Missing Parts/ Incomplete Application <input type="checkbox"/> Reply to Missing Parts under 37 CFR 1.52 or 1.53		

SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT

Firm Name			
Signature			
Printed name	Palaiyur S. Kalyanaraman		
Date	05/02/2005	Reg. No.	34,634


CERTIFICATE OF TRANSMISSION/MAILING

I hereby certify that this correspondence is being facsimile transmitted to the USPTO or deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on the date shown below:

Signature			
Typed or printed name			Date

This collection of information is required by 37 CFR 1.5. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.



FORM PTO-1449

U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICEATTY. DOCKET NO.:
OC01617K1APPLICATION NO.:
10/776, 988INFORMATION DISCLOSURE STATEMENT
BY APPLICANTAPPLICANT:
Timothy J. Guzi et al.

(Use several sheets if necessary)

FILING DATE:
02/11/2004

GROUP:

U.S. PATENT DOCUMENTS

*EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE IF APPROPRIATE
AA	5,571,813	11/05/1996	Rühter et al.			
AB	5,602,136	02/11/1997	Rühter et al.			
AC	5,602,137	02/11/1997	Rühter et al.			
AD	5,688,949	11/18/1997	Inoue et al.			
AE	5,707,997	01/13/1998	Shoji et al.			
AF	5,919,815	07/06/1999	Bradley et al.			
AG	6,040,321	03/21/2000	Kim et al.			
AH	6,107,305	08/22/2000	Misra et al.			
AI	6,191,131	02/20/2001	He et al.			
AJ	6,262,096	07/17/2001	Kim et al.			
AK	6,413,974	07/02/2002	Dumont et al.			

FOREIGN PATENT DOCUMENTS

	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION
						YES
						NO
AL	DE 102 23 917 A1	11/12/2003	Germany			
AM	EP 0 628 559	04/03/2002	Europe			
AN	EP 1 334 973	08/13/2003	Europe			
AO	WO 02/22610	03/21/2002	PCT			
AP	WO 02/40485	05/23/2002	PCT			
AQ	WO 02/50079	06/27/2002	PCT			
AR	WO 03/091256 A1	11/06/2003	PCT			
AS	WO 95/35298	12/28/1995	PCT			

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

AT	Vesely et al., "Inhibition of Cyclin-Dependent Kinases by Purine Analogues", <i>Eur. J. Biochem</i> (1994), 224 : 771-786.
AU	Kim et al., "Discovery of Aminothiazole Inhibitors of Cyclin-Dependent Kinase 2: Synthesis, X-ray Crystallographic Analysis, and Biological Activities", <i>Journal of Medical Chemistry</i> , (2002), 45 : 3905-3927.
AV	Mettey et al., "Aloisines, a New Family of CDK/GSK-3 Inhibitors. SAR Study, Crystal Structure in Complex with CDK2, Enzyme Selectivity, and Cellular Effects", <i>J. Med. Chem.</i> (2003), 46 (2): 222-236.
AW	Novinson et al., "Synthesis and Antifungal Properties of Certain 7-Alkylaminopyrazolo[1,5-a]pyrimidines", <i>J. Med. Chem.</i> (1977), 20 (2): 296-299.
AX	Senderowicz et al., "Phase I Trial of Continuous Infusion Flavopiridol, a Novel Cyclin-Dependent Kinase Inhibitor, in Patients with Refractory Neoplasms", <i>Journal of Clinical Oncology</i> (September 1998), 16 (9): 2986-2999.
AY	Meijer et al., "Biochemical and Cellular Effects of Roscovitine, a Potent and Selective Inhibitor of the Cyclin-Dependent Kinases CDC2, CDK2 and CDK5", <i>Eur. J. Biochem.</i> (1997), 243 :527-536.

EXAMINER

DATE CONSIDERED

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO-1449 INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTY. DOCKET NO.: OC01617K1	APPLICATION NO.: 10/776,988
			APPLICANT: Timothy J. Guzi et al.	
			FILING DATE: 02/22/2004	GROUP:
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)				
AZ	Bible <i>et al.</i> , "Cytotoxic Synergy Between Flavopiridol (NSC 649890, L86-8275) and Various Antineoplastic Agents: The Importance of Sequence of Administration", <i>Cancer Research</i> (August 15, 1997), 57 : 3375-3380.			
BA	Shiota <i>et al.</i> , "Synthesis and Structure-Activity Relationship of a New Series of Potent Angiotensin II Receptor Antagonists: Pyrazolo[1,5-a]pyrimidine Derivatives", <i>Chem. Pharm. Bull.</i> (1999), 47 (7): 928-938.			
BB	Translation of WO 03/91256, <i>A Rising Sun Communications Ltd. Translation Product</i> , (1-62)			
BC	Yasuo Makisumi, "Studies on the Azaindolizine Compounds. XI. Synthesis of 6,7-Disubstituted Pyrazolo[1,5-a]pyrimidines.", <i>Chem. Pharm. Bull.</i> (1962), 10 : 620-626.			
BD	Cai <i>et al.</i> , "5-(N-Oxyaza)-7-substituted-1,4-dihydroquinoxaline-2,3-diones: Novel, Systemically Active and Broad Spectrum Antagonists for NMDA/glycine, AMPA, and Kainate Receptors", <i>J. Med. Chem.</i> (1997), 40 :3679-3686.			
BE	Bruce L. Finkelstein, "Regioselective Lithiation and Reaction of [1,2,4]Triazolo[1,5-a]pyridine and Pyrazolo[1,5-a]pyridine", <i>J. Org. Chem.</i> , (1992), 57 : 5538-5540.			
BF	Ongkeko <i>et al.</i> , "Inactivation of Cdc2 increases the level of apoptosis induced by DNA damage", <i>Journal of Cell Science</i> (1995), 108 : 2897-2904.			
BG	Shiota <i>et al.</i> , "Regioselective Reactions of Organozinc Reagents with 2,4-Dichloroquinoline and 5,7-Dichloropyrazolo[1,5-a]pyrimidine", <i>J. Org. Chem.</i> (1999), 64 : 453-457.			
BH	Novinson <i>et al.</i> , "Synthesis and Antimicrobial Activity of Some Novel Heterocycles. Azolo-a-s-triazines ¹ ", <i>Journal of Medicinal Chemistry</i> , (1976), 19 (4): 517-520.			
BI				
EXAMINER		DATE CONSIDERED		
<small>*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.</small>				